{"prompt": "['The first patient self-administered two doses of aPCC 94 units/kg in 2 days to treat his left', 'knee hemarthrosis. The next day, he started experiencing icterus and severe back pain', 'and the patient self-administered two doses of rFVIIa 85 g/kg and two doses of aPCC', '94 units/kg. Then the patient presented with thrombocytopenia, hyperbilirubinemia, and', 'acute renal failure with schistocytes on peripheral blood smears. The patient was', 'diagnosed with TMA and treated with plasmapheresis, hemodialysis, and supportive', 'care and his condition improved and resolved after 16 days. The patient discontinued', 'treatment with emicizumab', 'The second patient self-administered five doses of aPCC 74 units/kg over three', 'consecutive days before the serious adverse event onset. The patient had abdominal', 'pain and emesis, acute renal failure, thrombocytopenia, elevated LDH, and a low', 'haptoglobin with schistocytes on peripheral blood smears. The patient was diagnosed', 'with TMA and recovered without plasmapheresis or hemodialysis after 18 days. The', 'patient restarted treatment with emicizumab after resolution of the serious adverse event', 'without recurrence of TMA.', 'The third patient presented at the hospital complaining of rectal bleeding, postural dizziness, and', 'exertional dyspnea. Of note,', 'Multiple doses of rFVIIa were administered and various interventions', '(hemostatic powder application, absorbable hemostat packing, and embolization of rectal arteries)', 'were used in an attempt to control bleeding. Despite these measures, the patient continued to have', \"rectal hemorrhage. The patient's bypassing agent treatment was then changed to aPCC and\", 'temporary cessation of bleeding was achieved. Subsequently, the patient developed a serious', 'adverse event of TMA following concomitant bypassing agent treatment. Emicizumab', 'prophylaxis and aPCC were discontinued and therapeutic plasma exchange with albumin was', \"provided. Three days later, investigators assessed the patient's TMA to be improving based on\", 'laboratory assessments (LDH and platelet count). However, the patient experienced recurrent', 'rectal hemorrhage. Surgery and arterial embolization were no longer deemed to be feasible and the', 'patient was placed on comfort care before passing away the same day. The investigator assessed', 'the patient death as related to the serious adverse event of rectal hemorrhage and unrelated to', 'emicizumab, and the TMA as related to emicizumab and aPCC. For more details please refer to', \"the Emicizumab Investigator's Brochure.\", 'These events should be reported as adverse events of special interest (see Section 5.2.3), and also as', 'serious adverse events if it meets criteria as described in Section 5.2.2. HCPs should educate', 'patients/caregivers to recognize signs and symptoms of potential TMA (i.e., confusion, weakness,', 'swelling of arms and legs, yellowing of skin and eyes, vague abdominal or back pain, nausea,', 'vomiting, or decreased urination, etc.) and ensure that they understand the importance of seeking', 'appropriate medical attention. Patients and/or caregivers will also receive two alert cards to remind', 'them of this information and these instructions should TMA be suspected.', '5.1.1.4', 'Hypersensitivity', 'Since emicizumab is a biological product, acute systemic hypersensitivity reactions,', 'including anaphylactic/anaphylactoid reactions, may occur. In Study ACE001JP, no severe', 'hypersensitivity reactions or anaphylactic/anaphylactoid reactions have been observed.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '127 / Protocol MO39129, Version 3']['These events should be reported as serious adverse events or adverse events of special', 'interest as described in Sections 5.2.2 and 5.2.3, respectively.', 'HCPs administering emicizumab in the clinic must be trained in the appropriate administration', 'procedures; be able to recognize the signs and symptoms associated with potential', 'hypersensitivity, anaphylactic, and anaphylactoid reactions; and should be familiar with', \"Sampson's criteria for defining anaphylaxis (Sampson et al. 2006; see Appendix 4). HCPs\", 'should also instruct patients how to recognize the signs and symptoms of hypersensitivity,', 'anaphylactic, and anaphylactoid reactions and to contact an HCP or seek emergency care in', 'case of any such occurrence. Patients/caregivers will also receive two alert cards to remind', 'them of this information should any of these reactions occur.', 'Patients with a history of clinically significant hypersensitivity reaction associated with', 'monoclonal antibody therapies or to the components of the emicizumab injection will be', 'excluded from study participation.', '5.1.2', 'Management of Patients Who Experience Specific Adverse Events', 'Guidelines for management of specific adverse events are outlined in Table 1.', 'Table 11', 'Guidelines for Management of Patients Who Experience Specific Adverse', 'Events', 'Event', 'Action to Be Taken', 'Injection-site reactions', 'Injection-site reactions should be treated as clinically indicated.', 'Emicizumab should not be injected into areas where the skin is', 'red, bruised, tender, or hard or into areas where there are', 'moles or scars.', 'In the clinic setting, patients will be monitored for signs of', 'injection-site reactions in the period immediately following', 'injections. Patients will be given guidance on how to report', 'injection-site reactions when administering drug at home or', 'after they leave the clinic.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '128 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}